Oral Molnupiravir and Nirmatrelvir/Ritonavir for the Treatment of COVID-19: A Literature Review with a Focus on Real-World Evidence
Vaccines remain the cornerstone of medical prevention and are highly effective in reducing the risk of severe disease and death due to coronavirus disease 2019 (COVID-19). In the context of expanding the therapeutic armamentarium against COVID-19, molnupiravir (Lagevrio) and ritonavir-boosted nirmat...
Saved in:
Main Authors: | Ioannis Karniadakis (Author), Nikolaos Mazonakis (Author), Constantinos Tsioutis (Author), Michail Papadakis (Author), Ioulia Markaki (Author), Nikolaos Spernovasilis (Author) |
---|---|
Format: | Book |
Published: |
MDPI AG,
2023-10-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Molnupiravir and Nirmatrelvir/Ritonavir: The New Available Antiviral Options for COVID-19
by: Samuel Theodorus Sutanto, et al.
Published: (2022) -
Molnupiravir, Nirmatrelvir/Ritonavir, or Sotrovimab for High-Risk COVID-19 Patients Infected by the Omicron Variant: Hospitalization, Mortality, and Time until Negative Swab Test in Real Life
by: Luca Cegolon, et al.
Published: (2023) -
Nirmatrelvir/Ritonavir for hemodialysis patients with COVID-19
by: Jiayue Lu, et al.
Published: (2023) -
Economic Evaluation of Nirmatrelvir/Ritonavir Among Adults Against Hospitalization During the Omicron Dominated Period in Malaysia: A Real-World Evidence Perspective
by: Ee Vien Low, et al.
Published: (2024) -
Association of Molnupiravir and Nirmatrelvir-Ritonavir with preventable mortality, hospital admissions and related avoidable healthcare system cost among high-risk patients with mild to moderate COVID-19
by: Abraham Ka-Chung Wai, et al.
Published: (2023)